Aggiornamento monografico
Le istiocitosi dell’infanzia
HISTIOCYTOSIS IN CHILDHOOD
MARCO RABUSIN, PAOLO TAMARO, GIULIO ZANAZZO
Clinica Pediatrica, Centro di Emato-Oncologia, IRCCS “Burlo Garofolo”, Trieste
Febbraio 1999 - pagg. 87 -94
Abstract
Histiocyte disorders in childhood are caracterized by tissue infiltration with cells of the monocyte/
macrophage lineage. Two disorders, Langerhans cell histiocytosis (LCH), and hemophagocytic
lymphohistiocytosis (HLH), account for the majority of cases in childhood
and are now classified as class one and class two histiocytosis. Althought both LHC and
HLH are considered reactive disorders, the prognosis is variable, ranging from self-limited
disease to multisystem life-threatening disorder. Malignant histiocytosis is classified as class
three, together with acute monocytic leukemia and histiocytic lymphoma. Treatment protocols
vary along with the type and severity of the disease and should comprise treatment of
the primary infection if an infectious agent is identified.
Parole chiave
Suggerite dall'AI
Classificazione MeSH
Bibliografia
1. Writing Group of the Histiocyte Society:
Histiocytosis syndromes in children. Lancet
1, 208-209, 1987.
2. Lichtestein L: Histiocytosis X: integration of eosinophilic granuloma of bone, Letterer- Siwe disease and Schuller-Christian disease as related manifestation of a single nosologic entity. AMA Arch Pathol 56, 84-102, 1953.
3. Broadbent V, Egeler RM, Nesbit ME: Langerhans’cell histiocytosis-clinical and epidemiological aspects. Br J Cancer 70, suppl XXIII, S11-S16, 1994.
4. Egeler RM, D’Angio G: Langerhans cell histiocytosis. Pediatrics 127, 1-11, 1995.
5. Kilpatrick S, Wenger D, Gilchrist G, et al: Langerhans’ Cell Histiocytosis of Bone. Cancer Vol. 76, 12, 2471-2484, 1995.
6. Grois N, Favara B, Mostbeck G, Prayer D: Central nervous system in Langerhans cell Histiocytosis. Hem/Onc Clinics of North Am 12, 2, 287-305, 1998.
7. Ladisch S, Gadner H: Treatment of Langerhans’ cell histiocytosis-evolution and current approaches. Br J Cancer 70, suppl. XXIII, S41-S46, 1994.
8. Gadner H, Heitger A, Grois N, Gatter- Menz I, et al: Treatment strategy for disseminated Langerhans’ cell histiocytosis. Med Ped Oncology 23, 72-80, 1994.
9. Mahmoud HH, Wang WC, Murphy SB: Cyclosporine therapy for advanced Langerhans cell histiocytosis. Blood 77, 721-25, 1991.
10. Kelly KM, Beverley PC, Chu AC: Successful in vivo immunolocalization of Langerhans’ cell histiocytosis with use of a monoclonal antibody, NA1/34. Pediatrics 125, 717-22, 1994.
11. Henter J-I, Soder O, Ost A. Elinder G: Incidence and clinical features of familial hemophagocytic lymphohistiocytosis in Sweden. Acta Ped Scand 80, 428-435, 1991.
12. Arico M, Janka G, Fischer A, et al: Hemophagocytic lymphoistiocytosis: diagnosis, treatment and prognostic factors: report of 122 children from the International Registry. Leukemia 10, 197-203, 1996.
13. Filipovich A: Hemophagocytic lymphohistiocytosis: a lethal disorder of immune regolation. Pediatrics 130, 337-38, 1997.
14. Henter JI, Nemmesmo I: Neuropathological findings and neurologic symptoms in 23 children with hemophagocytic limphohistiocytosis. Pediatrics 130, 358-65, 1997.
15. Henter JI, Elinder G, Ost A and the FHL Study Group of the Histiocyte Society: Diagnostic guidelines for hemophagocytic limphohistiocytosis. Semin. Oncology 18, 29- 33, 1991.
16. Baker KS, DeLaat C, Shapiro R, Gross TG, Steinbuch M, Filipovich A: Successful correction of hemophagocytic lymphohistiocytosis with related and unrelated bone marrow transplantation. Blood 86, suppl 1: 387a, 1995.
17. Imashuku S, Hibi S, Todo S: Hemophagocytic lymphoistiocytosis in infancy and childhood. Pediatrics 1997; 130: 352-57.
18. Henter JI, Aricň M, Egeler R. for the FHL Study Group of the Histiocyte Society. HLH- 94: a treatment protocol for hemophagocytic lymphohistiocytosis. Med and Ped Oncology 28, 342-47, 1997.
19. Sacchi S, Artusi T, Torelli U, Emilia G: Sinus histiocytosis with massive lymphadenopathy. Leukemia Lymphoma 7, 189-94, 1992.
20. Egeler RM, Schmitz L, Sonneveld P, Mannival C, et al: Malignant histiocytosis: a reassessment of cases fromerly classified as histiocytic neoplasm and review of the literature. Med and Ped Oncology 25, 1-7, 1995.
21. Brugieres L, Caillaud JM, Patte C, et al: Malignant histiocytosis: therapeutic results in 27 children treated with a single polychemotherapy regimen. Med and Ped Oncology 17, 193-6, 1989.
2. Lichtestein L: Histiocytosis X: integration of eosinophilic granuloma of bone, Letterer- Siwe disease and Schuller-Christian disease as related manifestation of a single nosologic entity. AMA Arch Pathol 56, 84-102, 1953.
3. Broadbent V, Egeler RM, Nesbit ME: Langerhans’cell histiocytosis-clinical and epidemiological aspects. Br J Cancer 70, suppl XXIII, S11-S16, 1994.
4. Egeler RM, D’Angio G: Langerhans cell histiocytosis. Pediatrics 127, 1-11, 1995.
5. Kilpatrick S, Wenger D, Gilchrist G, et al: Langerhans’ Cell Histiocytosis of Bone. Cancer Vol. 76, 12, 2471-2484, 1995.
6. Grois N, Favara B, Mostbeck G, Prayer D: Central nervous system in Langerhans cell Histiocytosis. Hem/Onc Clinics of North Am 12, 2, 287-305, 1998.
7. Ladisch S, Gadner H: Treatment of Langerhans’ cell histiocytosis-evolution and current approaches. Br J Cancer 70, suppl. XXIII, S41-S46, 1994.
8. Gadner H, Heitger A, Grois N, Gatter- Menz I, et al: Treatment strategy for disseminated Langerhans’ cell histiocytosis. Med Ped Oncology 23, 72-80, 1994.
9. Mahmoud HH, Wang WC, Murphy SB: Cyclosporine therapy for advanced Langerhans cell histiocytosis. Blood 77, 721-25, 1991.
10. Kelly KM, Beverley PC, Chu AC: Successful in vivo immunolocalization of Langerhans’ cell histiocytosis with use of a monoclonal antibody, NA1/34. Pediatrics 125, 717-22, 1994.
11. Henter J-I, Soder O, Ost A. Elinder G: Incidence and clinical features of familial hemophagocytic lymphohistiocytosis in Sweden. Acta Ped Scand 80, 428-435, 1991.
12. Arico M, Janka G, Fischer A, et al: Hemophagocytic lymphoistiocytosis: diagnosis, treatment and prognostic factors: report of 122 children from the International Registry. Leukemia 10, 197-203, 1996.
13. Filipovich A: Hemophagocytic lymphohistiocytosis: a lethal disorder of immune regolation. Pediatrics 130, 337-38, 1997.
14. Henter JI, Nemmesmo I: Neuropathological findings and neurologic symptoms in 23 children with hemophagocytic limphohistiocytosis. Pediatrics 130, 358-65, 1997.
15. Henter JI, Elinder G, Ost A and the FHL Study Group of the Histiocyte Society: Diagnostic guidelines for hemophagocytic limphohistiocytosis. Semin. Oncology 18, 29- 33, 1991.
16. Baker KS, DeLaat C, Shapiro R, Gross TG, Steinbuch M, Filipovich A: Successful correction of hemophagocytic lymphohistiocytosis with related and unrelated bone marrow transplantation. Blood 86, suppl 1: 387a, 1995.
17. Imashuku S, Hibi S, Todo S: Hemophagocytic lymphoistiocytosis in infancy and childhood. Pediatrics 1997; 130: 352-57.
18. Henter JI, Aricň M, Egeler R. for the FHL Study Group of the Histiocyte Society. HLH- 94: a treatment protocol for hemophagocytic lymphohistiocytosis. Med and Ped Oncology 28, 342-47, 1997.
19. Sacchi S, Artusi T, Torelli U, Emilia G: Sinus histiocytosis with massive lymphadenopathy. Leukemia Lymphoma 7, 189-94, 1992.
20. Egeler RM, Schmitz L, Sonneveld P, Mannival C, et al: Malignant histiocytosis: a reassessment of cases fromerly classified as histiocytic neoplasm and review of the literature. Med and Ped Oncology 25, 1-7, 1995.
21. Brugieres L, Caillaud JM, Patte C, et al: Malignant histiocytosis: therapeutic results in 27 children treated with a single polychemotherapy regimen. Med and Ped Oncology 17, 193-6, 1989.